

# TaRGETed Therapy with Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy (TaRGET)

A multi-centre, placebo-controlled, double-blinded, trial of tideglusib in genotype positive arrhythmogenic cardiomyopathy



Population Health  
Research Institute  
HEALTH THROUGH KNOWLEDGE




CIHR IRSC

 Canadian Institutes of Health Research | Instituts de recherche en santé du Canada



# Trial design

**Multicentre, double-blinded, placebo-controlled, parallel group, randomised controlled trial**



**Hypothesis:** Tideglusib treatment will reduce the frequency of premature ventricular complexes (PVCs) in patients with arrhythmogenic cardiomyopathy (ACM)

# Participating Canadian Sites

- Ontario
  - Hamilton General Hospital
  - Toronto General Hospital
  - London Health Sciences Centre
  - Ottawa Heart Institute
  - Kingston General Hospital
  - St. Michael's Hospital
  - Sunnybrook Hospital
  - Centenary Hospital
  - Southlake Regional Health Centre
- Nova Scotia
  - Queen Elizabeth II Health Sciences Centre
- Newfoundland
  - Health Sciences Centre
- Quebec
  - Montreal Heart Institute
  - McGill University Health Centre
  - Quebec Heart and Lung Institute
  - Hospital of the Sacre Coeur
- British Columbia
  - University of British Columbia
- Alberta
  - University of Calgary
- Manitoba
  - University of Manitoba

